Who Should Not Get MDMA-Assisted Therapy: Heart Risks, Drug Interactions and Screening

Most of the argument about MDMA-assisted therapy is about whether it works. Less attention goes to the part regulators and clinicians consider settled: it is a medicine with real physiological effects, and it is unsafe for identifiable groups of people. That is not a caveat bolted on at the end. It is the reason the treatment is delivered under supervision at all.

The cardiovascular problem

MDMA is sympathomimetic — it pushes heart rate and blood pressure up. In the Phase 3 trial published in Nature Medicine, cardiac treatment-emergent adverse events occurred in seven participants in the MDMA group and one in the control group, including palpitations in 9.4% of MDMA recipients versus 2.0% of controls, plus two cases of tachycardia. All were graded mild. Vascular events occurred in nine MDMA recipients, all mild except one.

"Mild" in a monitored trial is a very different thing from "mild" in an unsupervised setting. The American Journal of Psychiatry review notes that under trial conditions blood pressures generally remained below the hypertensive threshold of 140/90 — which is a statement about what monitoring achieved, not a claim that the drug leaves blood pressure alone.

Who was excluded from the trials

Trial protocols excluded people with documented significant cardiovascular risk factors including uncontrolled hypertension, as well as those with cardiac disease or arrhythmia, history of stroke, liver disease, a history of epilepsy, hyponatraemia, or malignant hyperthermia. Pregnancy and breastfeeding were excluded. So were people with current substance dependence and, in most protocols, those with active suicidality or a psychotic-spectrum diagnosis.

The clinical practice guidance from the Australian and New Zealand psychiatric college treats those exclusions as a floor rather than a suggestion: it makes a strong recommendation against using MDMA-assisted psychotherapy in patient groups excluded from the trials for safety reasons.

Drug interactions that matter

• MAOIs. Contraindicated. Combining an MAOI with MDMA risks serotonin syndrome, which can be fatal.
• SSRIs and SNRIs. Commonly present in this population and genuinely complicated: they can blunt MDMA's subjective effects, and the combination carries serotonin-syndrome risk. Trial protocols typically required tapering antidepressants before dosing, which is itself a clinical decision with withdrawal consequences.
• Blood pressure medication. Relevant both ways — uncontrolled hypertension rules people out, and controlled hypertension required individual assessment in trial protocols.
• Lithium and other serotonergic agents. Reported as risky in the practical-guidance literature and generally avoided.

Why the screening is the treatment

The safety record that trial sponsors point to — no serious treatment-emergent adverse events attributed to the medicine in the confirmatory programme — was produced under a specific set of conditions: a screened population, two trained therapists, vital-sign monitoring, a defined discharge standard, and a follow-up schedule. Each of those is load-bearing. Remove the screening and the adverse-event statistics no longer describe what you are doing.

This is also why the difference between a clinical trial, a licensed authorised-prescriber service, and an unregulated offer matters so much. The published safety numbers were earned by the first two. They cannot be transferred to the third.

What a safe screening should include

• Blood pressure measurement, and a decision about whether it is controlled enough.
• A full medication list with an explicit check for MAOIs, SSRIs, SNRIs, lithium and blood-pressure drugs.
• Cardiac history, and an ECG where risk factors are present.
• Liver function and a review of any condition that lowers seizure threshold.
• An honest assessment of current substance use and of suicidality, with a written plan.

None of that is exotic medicine. It is the same pre-procedure thinking any clinic would apply to a drug that moves blood pressure. The reason it needs saying here is that the treatment's popularity has outrun the screening that makes it defensible.